Trials / Not Yet Recruiting
Not Yet RecruitingNCT06895525
Efficacy of HellenCare in Early-Stage Alzheimer's Disease
The HEART Study: A Randomized, Double-Blind, Parallel Placebo-Controlled Trial on the Efficacy of HellenCare in Early-Stage Alzheimer's Disease
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Peking University First Hospital · Academic / Other
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate whether HellenCare, a multicomponent nutraceutical, improves cognitive and functional outcomes in patients with early-stage Alzheimer's disease (AD). The investigators will compare changes in outcomes between the HellenCare group and the placebo group to determine if the intervention is effective and safe.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | HellenCare | 2 g, twice daily, to be taken on an empty stomach. |
| DIETARY_SUPPLEMENT | Placebo | 2 g, twice daily, to be taken on an empty stomach. |
Timeline
- Start date
- 2025-04-15
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2025-03-26
- Last updated
- 2025-04-08
Source: ClinicalTrials.gov record NCT06895525. Inclusion in this directory is not an endorsement.